Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination ...

Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...

Smart multi-target drugs are redefining how we treat complex diseases by combining AI-driven discovery with mechanistic ...

The Nutraceutical Excipients Market was valued at USD 4.5 billion in 2024, reflecting strong expansion driven by the rising consumption of dietary supplements and functional nutrition products. As ...

Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for individuals living with blood ...

Black cumin seeds contain diverse secondary metabolites, including thymoquinone, flavonoids, triterpenoids and alkaloids, ...

Denali's validated platform, strategic pipeline, and experienced management present a compelling long-term investment opportunity. Find out why DNLI stock is a Buy.

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 ...

Vascarta Inc., is pleased to share results from a new study led by researchers at the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER), with scientists at the ...

This acceptance follows Sangamo’s meeting with the FDA in October 2025 to discuss the proposed efficacy and safety data package for isaralgagene civaparvovec where, in the meeting minutes, among other ...

A new class of cancer drug has been pushed to an almost unimaginable level of potency in the lab, with researchers reporting ...

Skincare has transformed from a luxury to an accessible, personalised experience with AI, home devices and advanced ...